bufalin and mk 2206

bufalin has been researched along with mk 2206 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cao, Y; Li, JM; Tong, J; Wang, Y; Wu, YL; Xiang, RF; Xu, WB; Yan, H; Zhang, N	1

Other Studies

1 other study(ies) available for bufalin and mk 2206

Article	Year
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell death & disease, 2017, 05-11, Volume: 8, Issue:5 Topics: Animals; Bufanolides; Cell Line, Tumor; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2017

Article

Year

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.

Cell death & disease, 2017, 05-11, Volume: 8, Issue:5

Topics: Animals; Bufanolides; Cell Line, Tumor; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017